Ted Danson's new show will feature AI effort to treat disease

Danielle Brown | | Health Exec | Precision Medicine

A television series led by actor Ted Danson will showcase how a company is using various technologies, including AI, to help treat type 2 diabetes in India.

"The Advancements with Ted Danson" television series is planning to feature genomics and precision medicine company Shivom in an upcoming episode. The company is using its data and technology—like genomics, blockchain and AI—to help improve the diagnosis and treatment of type 2 diabetes in India. Type 2 diabetes affects about 72 million people in India, and incidences have quadrupled in the last 35 years, according to Shivom.

“The process will involve collecting saliva samples of the patients from which DNA will be extracted, analyzed and secured on Shivom’s blockchain-based genomics datahub. Shivom’s partner—diagnostics leader Genetic Technologies Limited—will help analyze the collected anonymous genomic-samples and data with the goal of developing a diagnostic SNP panel specific to the Indian population,” the company said in a press release.

The show will air at 3:30 p.m. ET on Sunday, Dec. 16 on CNBC.

""
Danielle Brown

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”